NuvaRing Clotting Risk Doubled When Compared to Other Hormonal Birth Control
Written By: Rheingold, Valet, Rheingold, Ruffo & Giuffra LLP
Our firm was the first to file NuvaRing suits in state and federal courts. Before any national or global attention was drawn to a higher incidence of deep vein thrombosis, pulmonary emboli, strokes and clots in NuvaRing over users of traditional second generation combined hormonal birth control, our firm noticed an unusual amount of injuries in users. Notably, women who had used second generation birth control for years with no side effects seemed to have side effects soon into switching to NuvaRing.
A published on May 10, 2012 in the British Medical Journal reveals the risk of blood clots (venous thromboembolisms) in women using the vaginal ring called the NuvaRing. Danish researchers studied pregnant women ages 15-49 who were free of any prior thrombotic disease, between 2001 and 2010, and discovered that women who use vaginal rings like the NuvaRing for contraception have a 6.5 times increased risk of confirmed venous thrombosis compared with non-users of hormonal contraception. When compared to women using second generation hormonal birth control, the risk was 1.9x. The study reviewed data from 1.6million Danish women. In Europe, data collection so large is possible due to health care being maintained by the government. Privacy concerns with private insurance carriers prevent these studies in the United States. Women using hormonal birth control will benefit from knowing the signs of pending clot injuries.